Mohamad S.B., Nagasawa H., Uto Y., Hori H.

Comp. Biochem. Physiol., Part A Mol. Integr. Physiol. 132:1-8(2002) GeneRIF 4668 · Mapped (3)
Tumor cell alpha-N-acetylgalactosaminidase activity and its involvement in GcMAF-related macrophage activation. GeneRIF 4668

Kanekura T., Sakuraba H., Matsuzawa F., Aikawa S., Doi H., Hirabayashi Y., Yoshii N., Fukushige T., Kanzaki T.

J. Dermatol. Sci. 37:15-20(2005) GeneRIF 4668 · Mapped (3)
Structural analysis revealed biochemical and phenotypic differences in these Kanzaki patients with the R329Q and R329W mutation. GeneRIF 4668

Chabas A., Duque J., Gort L.

J. Inherit. Metab. Dis. 30:108-108(2007) GeneRIF 4668 · Mapped (3)
NAGA mutation p.D217N (c.649G>A) in exon 6 and mutation p.E325K (c.973G>A) in exon 8 may have roles in alpha-N-acetylgalactosaminidase deficiency with cardiomyopathy GeneRIF 4668

Greco M., Mitri M.D., Chiriaco F., Leo G., Brienza E., Maffia M.

Cancer Lett. 283:222-229(2009) GeneRIF 4668 · Mapped (3)
Specific enzymatic activity of serum alpha-N-acetylgalactosaminidase was significantly increased in stage III melanoma patients but not in early stages. GeneRIF 4668

Tajima Y., Kawashima I., Tsukimura T., Sugawara K., Kuroda M., Suzuki T., Togawa T., Chiba Y., Jigami Y., Ohno K. et al.

Am. J. Hum. Genet. 85:569-580(2009) GeneRIF 4668 · Mapped (11)
Use of a modified NAGA in the development of enzyme replacement therapy for Fabry disease is reported. GeneRIF 4668

Tomasic I.B., Metcalf M.C., Guce A.I., Clark N.E., Garman S.C.

J. Biol. Chem. 285:21560-21566(2010) GeneRIF 4668 · Mapped (8)
the active sites of human lysosomal enzymes alpha-galactosidase and alpha-N-acetylgalactosaminidase have interconvertible specificites GeneRIF 4668

Clark N.E., Metcalf M.C., Best D., Fleet G.W., Garman S.C.

Proc. Natl. Acad. Sci. U.S.A. 109:17400-17405(2012) PDB 4DO4 PDB 4DO5 PDB 4DO6 · Mapped (1)